Catalano MG, Fortunati N, Boccuzzi G Epigenetics modifications and therapeutic prospects in human thyroid cancer. Front Endocrinol (Lausanne). 2012 Mar 19;3:40. doi: 10.3389/fendo.2012.00040. eCollection 2012.
Ceolin L, Siqueira DR, Romitti M, Ferreira CV, Maia AL Molecular basis of medullary thyroid carcinoma: the role of RET polymorphisms. Int J Mol Sci. 2012;13(1):221-39. doi: 10.3390/ijms13010221. Epub 2011 Dec 27. Review.
Chow WA, Jiang C, Guan M Anti-HIV drugs for cancer therapeutics: back to the future? Lancet Oncol. 2009 Jan;10(1):61-71. doi: 10.1016/S1470-2045(08)70334-6. Review.
Dancey JE, Chen HX Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov. 2006 Aug;5(8):649-59. Review.
Dar AC, Das TK, Shokat KM, Cagan RL Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature. 2012 Jun 6;486(7401):80-4. doi: 10.1038/nature11127.
Das T, Cagan R Drosophila as a novel therapeutic discovery tool for thyroid cancer. Thyroid. 2010 Jul;20(7):689-95. doi: 10.1089/thy.2010.1637. Review.
Hundahl SA, Fleming ID, Fremgen AM, Menck HR A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]. Cancer. 1998 Dec 15;83(12):2638-48.
Schoffski P, E R., Muller S, Brose MS, Shah MH, Licitra LF, An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients with documented RECIST progression at baseline. ASCO 2012, June 1-5, 2012.
Segouffin-Cariou C, Billaud M Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. J Biol Chem. 2000 Feb 4;275(5):3568-76.
Sherman SI Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab. 2009 May;94(5):1493-9. doi: 10.1210/jc.2008-0923. Epub 2009 Mar 3. Review.
Vidal M, Larson DE, Cagan RL Csk-deficient boundary cells are eliminated from normal Drosophila epithelia by exclusion, migration, and apoptosis. Dev Cell. 2006 Jan;10(1):33-44.
Vidal M, Wells S, Ryan A, Cagan R ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. Cancer Res. 2005 May 1;65(9):3538-41.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
